The Europe Companion Diagnostics Market is expected to witness market growth of 18.1% CAGR during the forecast period (2019-2025).
Companion diagnostics is an in vitro medical device which offers essential information for safe and effective use of a biological output or a corresponding drug. The test also helps healthcare professionals to decide if a certain therapy product is beneficial to patients and can tackle any possible severe side effects.
The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.
Increased R&D of focused therapies, increasing demand for the personalized medication in developing markets, and the identification of new biomarkers under multiple circumstances in addition to a larger amount of unmet cancer therapy requirements, are altogether pushing the market towards exponential growth during the forecast period.
The market research report covers the analysis of key stake holders of the market.
Key Companies Profiled in the report include
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.3 Market Scope
1.4.1 Europe Companion Diagnostics Market, by Technology
1.4.2 Europe Companion Diagnostics Market, by Indication
1.4.3 Europe Companion Diagnostics Market, by Cancer Type
1.4.4 Europe Companion Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Companion Diagnostics Market by Technology
3.1 Europe Immunohistochemistry Market by Country
3.2 Europe Polymerase chain reaction (PCR) Market by Country
3.3 Europe Next generation sequencing (NGS) Market by Country
3.4 Europe In Situ Hybridization Market by Country
3.5 Europe Other Technology Market by Country
Chapter 4. Europe Companion Diagnostics Market by Indication
4.1 Europe Oncology Companion Diagnostics Market by Country
4.2 Europe Companion Diagnostics Market by Cancer Type
4.2.1 Europe Breast Cancer Companion Diagnostics by Country
4.2.2 Europe Colorectal Cancer Companion Diagnostics by Country
4.2.3 Europe Lung Cancer Companion Diagnostics by Country
4.2.4 Europe Blood Cancer Companion Diagnostics by Country
4.2.5 Europe Other Cancer Type Companion Diagnostics Market by Country
4.3 Europe Neurology Companion Diagnostics Market by Country
4.4 Europe Other Indications Companion Diagnostics Market by Country
Chapter 5. Europe Companion Diagnostics Market by Country
5.1 Germany Companion Diagnostics Market
5.1.1 Germany Companion Diagnostics Market by Technology
5.1.2 Germany Companion Diagnostics Market by Indication
126.96.36.199 Germany Companion Diagnostics Market by Cancer Type
5.2 UK Companion Diagnostics Market
5.3 France Companion Diagnostics Market
5.4 Russia Companion Diagnostics Market
5.5 Spain Companion Diagnostics Market
5.6 Italy Companion Diagnostics Market
5.7 Rest of Europe Companion Diagnostics Market
Chapter 6. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/peyion